Spots Global Cancer Trial Database for Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
Official Title: A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas
Study ID: NCT00040599
Interventions
Study Description
Brief Summary: The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hoag Cancer Center, Newport Beach, California, United States
Washington Hospital Center, Washington, District of Columbia, United States
Bay Pines VA Medical Center, Saint Petersburg, Florida, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Zentralklinik Bad Berka, Bad Berka, , Germany
University Hospital Dresden, Dresden, , Germany
University of Szeged Medical Center, Szeged, , Hungary
Uppsala University Hospital, Uppsala, , Sweden
Centre Pluridisciplinaire d'Oncologie, Lausanne, , Switzerland
Contact Details
Name: William Wegener, MD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
